NIO Inc. vs ResMed Inc. — how do they compare? NIO Inc. trades at $4.81 (market cap $12.55B), while ResMed Inc. trades at $197.45 (market cap $28.81B). The key difference: ResMed Inc. is far larger — about 2.3× NIO Inc.'s market cap, and ResMed Inc. pays a 1.21% dividend while NIO Inc. pays none. Which is the better fit depends on your goals.
| NIO | RMD | |
|---|---|---|
Market Cap | $12.55B | $28.81B |
Sector | Consumer Cyclical | Health |
52-Week High | $7.89 | $293.73 |
52-Week Low | $4.44 | $182.82 |
Enterprise Value | $11.78B | $27.99B |
Dividend Yield | — | 1.21% |
Signals from Pluang's Aura AI — not financial advice
NIO trades at $4.79, down 1.84% with bearish technical signals despite strong delivery growth. The company shows improving fundamentals with revenue reaching $87.49B in 2025 and narrowing losses, though it remains unprofitable with negative cash flow. Analyst sentiment is mixed with 54% buy ratings but technical indicators show selling pressure. Recent vehicle deliveries surged 62.9% year-over-year in June 2026, providing optimism for margin improvement.
NIO presents a high-risk opportunity with significant growth potential but persistent profitability challenges. The stock offers exposure to China's EV market expansion but faces execution risks and competitive pressures. While delivery momentum is strong, investors must weigh the company's cash burn against its market position and Goldman Sachs' recent upgrade to buy with $7 target.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →